Find out why.
intervention
therapy
preference
considerations
and benefits
See why neoadjuvant therapy may be considered for select patients.
The majority of soft tissue recurrences outside of the urinary tract took place ≤3 years after surgery.9
Recurrence by Tumor (T) Stage and Lymph Node Involvement9
Recurrence by Tumor (T) Stage and Lymph Node Involvement9
recurrence
(n=559)
recurrence*
(n=58)
(22%)
(33%)
recurrence
(n=559)
recurrence*
(n=58)
(43%)
(26%)
recurrence
(n=559)
recurrence*
(n=58)
(26%)
(8.6%)
recurrence
(n=559)
recurrence*
(n=58)
(44%)
(20%)
What is the potential benefit of neoadjuvant chemotherapy?
According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®):
National Comprehensive Cancer Network® (NCCN®) recommends cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy for certain patients with stage ll or lllA bladder cancer.1
Defined as the time from randomization to any of the following: Disease progression that precludes surgery, local or distant recurrence, or death from any cause
Defined as the time from randomization until death from any cause and is measured in the intent-to-treat population
A cisplatin-based neoadjuvant chemotherapy should be offered to eligible radical cystectomy patients prior to cystectomy.
Radical cystectomy with bilateral pelvic lymphadenectomy should be offered to surgically eligible patients with resectable nonmetastatic (M0) muscle-invasive bladder cancer.
AUA = American Urological Association.
These topics should be discussed with your appropriate patients with MIBC8:
Risks and benefits
of surgery
Lifestyle changes
associated with surgery
Potential benefits
of cisplatin-based neoadjuvant therapy
Identify if your patients with MIBC are appropriate for cisplatin-based neoadjuvant therapy.
For some patients, NCCN recommends neoadjuvant chemotherapy over adjuvant-based chemotherapy.1
NCCN recommends that patients meet these criteria.
NCCN recommends cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy for certain patients with stage II or IIIA bladder cancer.1
Neoadjuvant cisplatin-based therapy + radical cystectomy + pelvic lymph node dissection is a recommended treatment option for:
- Stage ll = cT2, N0, M01
- Stage lllA = cT3, N0, M0: cT4a, N0, M0; cT1–4a, N11
- Patients willing to accept urinary diversion8
Factors to consider1,16:
- Hearing
- Performance status
- Renal function
- Neuropathy
- Heart failure